Clinical Trials
326 trialsLow-Dose Radiotherapy in Treating Painful Bone Metastases in Patients With Multiple Myeloma
University of Southern California
IMPACT
University of Utah
HCMT/MM2401: Ph2 Study of Selinexor + Bispecific Antibody for RRMM
Duke University
FASTER
SCRI Development Innovations, LLC
Sirolimus Pre-conditioning on T Cell Activity and T-cell Engaging Bispecific Antibody Efficacy in Multiple Myeloma
University of Iowa
Isa-Rd for Frail and/or Much Older Patients With Newly Diagnosed Multiple Myeloma
UNC Lineberger Comprehensive Cancer Center
MASTER-2
University of Alabama at Birmingham
Safety and Efficacy of KSVCBD Injection in Multiple Myeloma Expressing CD19 and/or BCMA
Chinese PLA General Hospital
An AI-Generated, Personalized Question Prompt List Intervention for Patients With Hematologic Cancers
Washington University School of Medicine
TAPUR
American Society of Clinical Oncology
Loratadine for the Reduction of G-CSF Induced Bone Pain in Patients With Multiple Myeloma Undergoing Stem Cell Mobilization
Rutgers, The State University of New Jersey
Leflunomide, Pomalidomide, and Dexamethasone for the Treatment of Relapsed or Refractory Multiple Myeloma
City of Hope Medical Center
A Vaccine (VSV-hIFNβ-NIS) With or Without Cyclophosphamide and Combinations of Ipilimumab, Nivolumab, and Cemiplimab in Treating Relapsed or Refractory Multiple Myeloma, Acute Myeloid Leukemia or Lymphoma
Mayo Clinic
A Study of Voice as a Way to Monitor for Side Effects in People Receiving CAR T-Cell Therapy
Memorial Sloan Kettering Cancer Center
KOALA
Peter MacCallum Cancer Centre, Australia
A Cognitive Training Intervention for Improving Cognitive and Neurological Outcomes in Patients Undergoing Treatment for Relapsed or Refractory Multiple Myeloma or B-cell Non-Hodgkin Lymphoma
Ohio State University Comprehensive Cancer Center
Infectious Complications in Hematological Patients Under Treatment With Bispecific Antibodies.
Infanta Leonor University Hospital
Post-Transplant Maintenance Therapy With Isatuximab Plus Lenalidomide for High-Risk Multiple Myeloma Patients
M.D. Anderson Cancer Center
Neurocognitive Outcomes After Whole Brain Radiation Therapy for Hematologic Malignancies
M.D. Anderson Cancer Center
BELI(E)VE
Universitätsklinikum Hamburg-Eppendorf
FOCUS
Ohio State University Comprehensive Cancer Center
The Cancer Connected Access and Remote Expertise Beyond Walls Program to Provide In-Home Cancer Treatment and Improve Treatment Satisfaction in Cancer Patients Living in the Florida Panhandle and Surrounding Areas
Mayo Clinic
HALTAging-1
University of Nebraska
Study of Selinexor With Carfilzomib, Isatuximab and Dexamethasone for Patients With Relapsed and/or Refractory Multiple Myeloma
Hoosier Cancer Research Network
CM336-RI
Institute of Hematology & Blood Diseases Hospital, China
ROTATE
Yale University
TriPRIL CAR T Cells in Multiple Myeloma
Massachusetts General Hospital
Anonymization of Clinical Data From Pseudonymized Databases Collected as Part of Previus Clinical Trials on Multiple Myeloma
IRCCS Azienda Ospedaliero-Universitaria di Bologna
MMAPPIN' Study: Multiple Myeloma Analysis For Patient-specific Insights to Dissect Disease Heterogeneity
IRCCS Azienda Ospedaliero-Universitaria di Bologna
LONGEVITI
University of Alberta
Single Microdose Trial- CXCR4 PET Tracer - Pharmacokinetics and Pharmacodynamics of [68Ga]Ga-R54, a Radiopharmaceutical Directed Toward CXCR4 in Patients With Advanced Solid Neoplasia.
National Cancer Institute, Naples
DC/MM Fusion Vaccine With BCMA CAR-T in R/R MM
Beth Israel Deaconess Medical Center
Predicting Progression of Developing Myeloma in a High-Risk Screened Population (PROMISE)
Dana-Farber Cancer Institute
Feasibility and Safety of Collecting and Combining Autologous Hematopoietic Stem Cells With Chimeric Antigen Receptor (CAR) T-Cell Therapy in Subjects With Relapsed/Refractory Hematological Malignancies
Cedars-Sinai Medical Center
A Phase 1 Study of Vaccination With Dendritic Cell (DC)/Multiple Myeloma (MM) Fusions in Combination With Elranatamab in Relapsed or Refractory Multiple Myeloma
Beth Israel Deaconess Medical Center
Phase I/II Study of CAR.70- Engineered IL15-transduced Cord Blood-derived NK Cells in Conjunction With Lymphodepleting Chemotherapy for the Management of Relapse/Refractory Hematological Malignances
M.D. Anderson Cancer Center
ALPS
Fondazione IRCCS Policlinico San Matteo di Pavia
iCaRe2
University of Nebraska
MoTD
University of Birmingham
A Dietary Study for People With Multiple Myeloma
Memorial Sloan Kettering Cancer Center
BEAM-MM
Universitätsklinikum Hamburg-Eppendorf
FAST-M
University of Miami
PASCA -MM
Centre Leon Berard
Safety and Efficacy of CS1 CAR-T (WS-CART-CS1) in Subjects With Multiple Myeloma
Washington University School of Medicine
VAMOS
University Hospital, Toulouse
EMBRACE
Ontario Clinical Oncology Group (OCOG)
Frontline Combination CAR-T Cell Therapy for Multiple Myeloma or Plasmacytoma
Shenzhen Geno-Immune Medical Institute
Engineered Dendritic Cell Vaccines for Multiple Myeloma
Shenzhen Geno-Immune Medical Institute
A Study of Melphalan With or Without Siltuximab in People With Multiple Myeloma Having an Autologous Stem Cell Transplant
Memorial Sloan Kettering Cancer Center
MM-ZTE-II
Cliniques universitaires Saint-Luc- Université Catholique de Louvain